Cell morphology Sample Clauses

Cell morphology. Cell shape was primarily examined to check for particular morphological phenotypes that have been linked to cell invasion (Xxxxx and Xxxxxxxxx, 2015). Cancer cells are normally in contact with extracellular matrix which involves a crucial part of the tumour microenvironment influencing cancer progression and metastasis (Xxxxxxx and Xxxxx, 2011). Immunohistochemical analysis on primary breast tumour samples has in fact suggested that fibronectin expression correlates with poor prognosis and progression free survival (Xxx et al., 2013). In order to examine cell morphology while trying to retain some aspects of the tumour microenvironment, cells were seeded on fibronectin coated glass coverslips and stained with TRITC phalloidin that stains the actin filaments as a marker of cell shape. Cell morphology features such as cell area and circularity were thus measured. The relative cell elongation parameter was obtained by subtracting the circularity value from 1.
AutoNDA by SimpleDocs
Cell morphology. (A) Cells were seeded on fibronectin coated coverslips. Cells were subsequently fixed and stained with TRITC Phalloidin (red) indicating the actin cytoskeleton and DAPI (blue) indicating the nuclei. Scale bar = 10μm. Cells were imaged and analysis was performed on ImageJ to obtain (B) the cell area and (C) elongation index. Analysis was performed on 30 cells per experiment. Bars represent the mean values and error bars represent the SEM (N=3). The first observation that was made is that unlike the normal MCF10A cells, all the breast cancer cell lines that were evaluated grew as single cells while no colony forming capacity was observed (figure 3.5A). The absence of colony forming cells indicates the loss of ability to form cell-cell interactions. This is one of the primary characteristics of epithelial to mesenchymal transition (EMT) which is accompanied by loss of e-cadherin expression that normally maintains cell-cell junctions and tissue integrity (Thiery, 2002). This feature is consistent with the aggressive behaviour of triple negative breast cancer. The cells were also evaluated in terms of other morphological features such as their area and elongation. In terms of their area, this feature varied a lot across the cell panel with the basal-like HCC38 cells appearing to have the largest cell area (figure 3.5A, 3.5B). The MB-231 and MB- 436 which also express high levels of IQGAP3 (figure 3.2B) were shown to be the most elongated cells consistent with their mesenchymal phenotype (figure 3.5C) but also have small cell area (figure 3.5B). Nonetheless, levels of IQGAP3 expression do not appear to strongly correlate with a particular morphological feature.
Cell morphology. The time course of changes in cellular morphology by light microscopy following exposure to the placebo or Propanc compounds will be examined. If Propanc induces a change in morphology this might be indicative of a change in the expression of integrins (integrins are ‘receptors’ found on cell membranes that bind the extracellular matrix and bring about changes in cell shape (cytoskeleton), cell mobility and cell cycle). The expression of markers of epithelial cell-cell contacts (E-cadherin, beta-catenin) can also be investigated. This approach might be crucial to understanding how the drugs cross the epithelial barrier in the rectum. To address this question in more detail, it is likely that a model for transport across a single epithelial cell layer will need to be developed in the long term.

Related to Cell morphology

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • New Technology When new or updated technology is introduced into a workplace, it will be the responsibility of the employer to provide appropriate and, if necessary, ongoing training to the employees directly affected. Such training will include any health and safety implications or information that will enable employees to operate the equipment without discomfort and will help maintain their general well-being.

  • Speech Therapy This plan covers speech therapy services when provided by a qualified licensed provider and part of a formal treatment plan for: • loss of speech or communication function; or • impairment as a result of an acute illness or injury, or an acute exacerbation of a chronic disease. Speech therapy services must relate to: • performing basic functional communication; or • assessing or treating swallowing dysfunction. See Autism Services when speech therapy services are rendered as part of the treatment of autism spectrum disorder. The amount you pay and any benefit limit will be the same whether the services are provided for habilitative or rehabilitative purposes.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Prosthodontics We Cover prosthodontic services as follows: • Removable complete or partial dentures, for Members 15 years of age and above, including six (6) months follow-up care; • Additional services including insertion of identification slips, repairs, relines and rebases and treatment of cleft palate; and • Interim prosthesis for Members five (5) to 15 years of age. We do not Cover implants or implant related services. Fixed bridges are not Covered unless they are required: • For replacement of a single upper anterior (central/lateral incisor or cuspid) in a patient with an otherwise full complement of natural, functional and/or restored teeth; • For cleft palate stabilization; or • Due to the presence of any neurologic or physiologic condition that would preclude the placement of a removable prosthesis, as demonstrated by medical documentation.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

Time is Money Join Law Insider Premium to draft better contracts faster.